U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07154537) titled 'Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)' on Aug. 27.
Brief Summary: Multiple myeloma patients often get serious infections that can be deadly. A British study looked at newly diagnosed patients and found that bacterial infections were the main cause of death in the first 60 days, mostly from pneumonia (66%) and blood poisoning (23%). The most common bacteria causing these infections were pneumococcus, staph, and E. coli.
Medical experts recommend that multiple myeloma patients get pneumonia vaccines. However, some studies show these vaccines don't work well in these patients, raising quest...